Rigel Pharma (RIGL) volatility elevated into topline results
Up)
Rigel Pharma (Nasdaq: RIGL) : Rigel Pharma, a late stage development company, closed at $12.23. Investors are expecting phase 2B data for R788 in rheumatoid arthritis in July. RIGL July call option implied volatility is at 155, puts are at 149, September calls are at 164, puts are at 160; verses its six-month average of 143 according to Track Data, suggesting larger price movement. Paul Foster
You May Also Be Interested In
- Savient Pharma (SVNT) Moves Higher with Volatility; Bumps Up Against Key Resistance Point
- Morgan Stanley (MS) Shares Pressured on Questionable Facebook (FB) Tactics; Hits Fresh 6-Month Low
- MSCI Brazil Index (EWZ) volatility elevated; index near an eight month-low
Create E-mail Alert Related Categories
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
